Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"
After almost two decades working for Novo Nordisk, Anders Dyhr Toft changes the scenery of his professional life to biotech company Synact Pharma to be the new CMO. According to the person in question, he felt the need to try out a different culture and pacing, as well as a new level of risk-taking.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
A freer bird now, but with smaller wings.
This is how Anders Dyhr Toft describes his life after swapping the job of corporate vice president for commercial innovation at Novo Nordisk for that of Chief Medical Officer at biotech firm Synact Pharma.
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.